Genentech news, articles and information:
 | 1/2/2007 - The U.S. Food and Drug Administration (FDA) announced Monday that two lupus patients had died of a rare brain infection after being prescribed the Genentech and Biogen drug Rituxan, which was not approved to treat lupus.
In a notice posted on its website, the FDA said Rituxan was approved to treat...
|
 | 10/13/2006 - Earlier this week the pharmaceutical firm Genentech announced that it would institute a price cap for its cancer drug Avastin at $55,000 per year for patients with a household income of less than $75,000 a year.
Genentech's announcement follows a decision by rival drug company Amgen two weeks ago...
|
| 9/27/2006 - Genentech's cancer-fighting drug Avastin's label now includes warnings related to a rare brain-bleeding condition and deterioration of nasal tissue that both have been associated with the drug. The FDA's website now notes that Avastin can possibly cause a rare brain-capillary leak syndrome that can...
|
Concept-related articles:Cancer:The FDA:Colon cancer:FDA:Avastin:Doctors:Blood:Patients:Colon:Treatment:Companies:Drug:Tumors:Disease:Medicine:Drugs:
|
 |
Concepts related to Genentech
View Genentech on NaturalPedia™
|
|